Jun 8, 2015
TSX Exchange Symbol: RVX
CALGARY, June 8, 2015 /CNW/ - Resverlogix Corp. (TSX: RVX) today announced that findings of a study performed by the Baker IDI Heart and Diabetes Institute, Melbourne, Australia and Resverlogix's scientists were reported at the 2015 ADA Scientific Sessions in Boston, MA. The presentation was entitled "Effects of the ApoA-I Inducer, RVX-208 on Glucose Metabolism in Individuals with Prediabetes Mellitus." The data in the presentation was based on patients with prediabetes mellitus who already had abnormal blood glucose levels. Treatment with RVX-208 (200 mg/day) for 29-33 days led to not only a reduction in glucose absorption but also suppression of endogenous glucose production. The significance of these findings are as follows: (1) short duration of RVX-208 treatment had effects on glucose metabolism, and (2) both the reduction in glucose absorption and production are expected to be of benefit in patients with prediabetes mellitus.
The above findings are intriguing when viewed in the light of additional new data arising from the same study reported at the recent International Society of Atherosclerosis (ISA) meeting, May 23-26, 2015 in Amsterdam, NL. At the ISA meeting, a presentation entitled, "The effects of a novel apoA-I transcriptional regulator (RVX-208) on whole plasma and HDL lipidomes," the same team of investigators detailed the ability of RVX-208 to change the lipid profile within the high-density lipoprotein (HDL) favouring normalization of the composition towards that observed in healthy individuals. Together, the data contained in the two presentations add to the idea that RVX-208 has the ability to affect glucose and lipid metabolism in ways that will be of benefit to patients with high cardiovascular disease (CVD) risks.
"The results arising from the study are enlightening because they show the effects of RVX-208, a selective bromodomain extra-terminal (BET) protein inhibitor, on glucose and lipids in patients with prediabetes mellitus," stated Dr. Norman Wong, chief scientific officer, Resverlogix. "As a physician who practices endocrinology, these findings give rise to added benefits of RVX-208 for patients who have CVD risks on top of metabolic abnormalities involving glucose and lipids. The findings also serve to introduce the idea of exploring the use of a BET inhibitor for treating metabolic abnormalities," further commented Dr. Wong.
About RVX-208
RVX-208 is a first-in-class, small molecule selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with DM and low HDL.
About Resverlogix
Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter https://twitter.com/resverlogix_rvx @Resverlogix_RVX.
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contacts:
Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: don@resverlogix.com
Sarah Zapotichny
Director of Investor Relations & Corporate Communications
Resverlogix Corp.
Phone : 403-254-9252
Email: sarah@resverlogix.com
SOURCE Resverlogix Corp.